Palatin Technologies (NASDAQ:PTN – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($1.29) EPS for the quarter, FiscalAI reports. The firm had revenue of $0.36 million for the quarter. Palatin Technologies had a negative net margin of 63.54% and a negative return on equity of 115.00%.
Palatin Technologies Price Performance
Palatin Technologies stock traded down $0.10 during mid-day trading on Monday, hitting $6.13. 18,717 shares of the company traded hands, compared to its average volume of 35,426. Palatin Technologies has a one year low of $4.51 and a one year high of $31.00. The firm has a market cap of $10.92 million, a PE ratio of -76.62 and a beta of 0.75.
Hedge Funds Weigh In On Palatin Technologies
A hedge fund recently bought a new position in Palatin Technologies stock. State Street Corp acquired a new stake in shares of Palatin Technologies (NASDAQ:PTN – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 14,000 shares of the company’s stock, valued at approximately $124,000. State Street Corp owned approximately 0.79% of Palatin Technologies as of its most recent filing with the SEC. 11.50% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
PTN has been the topic of several research analyst reports. Zacks Research assumed coverage on shares of Palatin Technologies in a report on Friday, November 6th. They issued a “hold” rating on the stock. HC Wainwright started coverage on Palatin Technologies in a research note on Friday, November 6th. They set a “buy” rating and a $12.00 price objective for the company. Finally, Weiss Ratings assumed coverage on Palatin Technologies in a research report on Wednesday, November 4th. They set a “sell (e+)” rating for the company. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Palatin Technologies has a consensus rating of “Hold” and a consensus price target of $12.00.
View Our Latest Report on Palatin Technologies
About Palatin Technologies
Palatin Technologies is a biopharmaceutical company that develops peptide-based medicines designed to act on specific receptors. Its research has focused primarily on the melanocortin system, which is involved in a range of biological functions and potential therapeutic applications. The company’s commercial product is Vyleesi (bremelanotide), an injectable prescription medicine approved in the United States to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Read More
- Five stocks we like better than Palatin Technologies
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
